Login to Your Account



Earnings Roundup

Arena Yanks MAA, Falls on Belviq Launch Delay in U.S.

By Jennifer Boggs
Managing Editor

Friday, May 3, 2013
us_resized.jpg

Shares of Arena Pharmaceuticals Inc. were down nearly 10 percent Friday following Thursday's after-market release of first-quarter earnings, which included news that the San Diego-based biotech is pulling its European marketing application for obesity drug Belviq (lorcaserin), though the bigger disappointment may be the ongoing delay in Belviq's U.S. launch.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription